Human familial amyotrophic lateral sclerosis with an H46R mutant Cu/Zn superoxide dismutase (SOD1) gene is characterized by initial muscle weakness and atrophy in the legs and a very longterm clinical course (approximately 15 years). Transgenic mice with this mutation generated in our laboratory occasionally showed aggregates in the anterior horns and axonal degeneration in all white matter sections of the spinal cord on plastic sections at the presymptomatic stages (12 and 16 weeks old), although conventional staining revealed no pathologic changes. At the symptomatic stages (20 and 24 weeks), loss of anterior horn neurons was observed. On plastic sections, aggregates were frequently seen not only in the anterior horns but also in the posterior horns and in all sections of white matter. Degenerated fibers were observed in the anterior and posterior roots as well as in white matter. Electron and immunoelectron microscopic observation revealed human SOD1-and ubiquitin-positive aggregates consisting of intermediate filaments in the anterior horn even from an early presymptomatic stage. Thus, H46R mutant SOD1 transgenic mice are characterized by widespread pathologic changes of the spinal cord that extend beyond the motor system, including many aggregates lacking vacuoles. The close pathologic similarity makes this animal model suitable for the investigation of human familial amyotrophic lateral sclerosis with the mutation.
INTRODUCTION
Since the initial report of Cu/Zn superoxide dismutase (SOD1) mutation involvement in familial amyotrophic lateral sclerosis (FALS), more than 100 mutations on all 5 exons of SOD1 have been identified (1) . Of the more than 100 mutations in humans, 3 mutant SOD1 transgenic (Tg) mice (G85R, G37R, and G93A) have been extensively characterized as Tg mouse models of FALS (2, 3) . Unlike the variable pattern of weakness in humans, weakness typically starts in the hindlimbs in mice between 3 and 12 months of age, depending on both the mutation and the level to which it is expressed. On the other hand, FALS with a novel point mutation (A to G, which results in an amino acid substitution of histidine-46 by arginine, H46R) in exon 2 of the SOD1 gene is autosomal dominant and has been reported in the Japanese population. It has some characteristic clinical manifestations: initial development of muscle weakness and atrophy in the lower extremities; a very slow progression of symptoms to the upper extremities; and bulbar muscles with intrafamilial variation of disease severity. To a lesser extent, pyramidal signs also develop. The average age at onset is approximately 40 to 50 years, and the mean disease duration is about 15 years (4Y6). In 1 study, the mean T SD age at the onset in 1 family is 49.6 T 10.9 years (n = 10) and duration after the onset is 17.3 T 10.7 years (n = 4), and in another family durations are 48 T 9.5 (n = 14) and 16.8 T 6.8 years (n = 9), respectively (4) . In another study, the disease duration of the family is 17.8 T 13.2 years with the age at onset being 42.9 T 4.7 years (n = 7) (5). In a third study, the average T SD age at disease onset in the families is 44.3 T 8.7 years (n = 17), and the mean disease duration is 12.0 T 7.6 years (n = 17), with a range of 6 to 30 years (6) . These clinical characteristics are reminiscent of the Bpseudopolyneuritic form^of amyotrophic lateral sclerosis (MariePatrikios-type) (7) . To date, no studies of pathologic changes in H46R Tg mice have been reported, but there is a report of an H46R mutant SOD1 Tg rat (8) . The spinal cords of Tg mice with the H46R mutant SOD1 gene were examined from the presymptomatic to symptomatic stages, and the findings were compared with cases of human FALS with the H46R mutant SOD1 gene. Copyright @ 200 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
We isolated a P1-derived artificial clone (dJ100A14) containing the full genomic human SOD1 gene. This clone was identified by screening a human genomic PAC library (9) using polymerase chain reaction with primer pairs specific to the human SOD1 gene. From this, we cloned an 11.5-kilobase (kb) EcoRI-BamHI fragment that contained the entire coding sequence and promoter region of the human SOD1 gene (10, 11) . The H46R mutation was engineered into this fragment by site-directed mutagenesis (Mutan-express Km, Takara, Otsu, Japan). To obtain the H46R mutation, an Ndel-Xbal fragment involving the second exon was subcloned into the pKF18k vector. Both the mutagenic primer and selection primer, which restored Km resistance, were hybridized to the vector and were incorporated during replication. The resulting potential Kmresistant clones were sequenced by the oligonucleotidedirected dual amber method (12) to verify the presence of the introduced mutation, H46R. A linear 11.5-kb EcoRIBamHI fragment containing the H46R mutation was microinjected into BDF1 (C57BL/6 Â DBA/2 F1) mouse (The Jackson Laboratory, Bar Harbor, ME) embryos. The treated embryos were transferred to oviducts of pseudopregnant ICR-slc female mice.
The DNA of newborn mice was extracted from their tails for human SOD1 gene-specific polymerase chain reaction amplification (forward primer: 5`-TTGGGAG GAGGTAGTGATTA; reverse primer: 5`-AGCTAGCAG GATAACAGATGA; 94-C for 30 seconds; 55-C for 30 seconds; 72-C for 30 seconds; 30 cycles). Founder mice were mated with C57B/6 mice (The Jackson Laboratory).
To generate Tg mice with the H46R mutation, we first obtained human genomic PAC clones encompassing the entire human SOD1 gene; we then subcloned this gene within an 11.5-kb EcoRI-BamHI fragment. Site-directed mutagenesis was used to generate clones with the H46R mutation. The mutated 11.5-kb EcoRI-BamHI fragments were microinjected into fertilized eggs from BDF1 mice. Eighty-three potential Tg H46R pups were obtained. From these, 3 founders with the H46R mutant transgene were identified using polymerase chain reaction and Southern blotting. One line with the H46R mutation developed motor neuron disease. This line expressed the highest level of the mutant SOD1.
To determine the level of the human mutant SOD1 protein that accumulated in the Tg line, spinal cord extracts were immunoblotted. The ratios of human mutant to mouse endogenous SOD1 were determined using an anti-human polyclonal antibody against a peptide sequence identical in human and mouse SOD1 (Calbiochem, San Diego, CA). The level of human mutant SOD1 protein in the line H46R-70 was 20.1 times the level of endogenous mouse SOD1. To determine the level of SOD1 activity, spinal cord extracts of Tg mice as well as those of controls were electrophoresed in native gels. SOD1 activity was quantified in situ on the gels using a well-established assay system in which dismutation of superoxide anion by SOD1 inhibits the conversion by superoxide anion of nitro blue tetrazolium to formazan, resulting in a formazan-free clear zone in an otherwise blue gel (13) . The level of SOD1 activity in the H46R-70 line was 20% of the control level.
The first sign of disease in this mutant line was weakness of limbs, primarily indicated by the dragging of 1 limb. In the H46R-70 line, all of the mice showed weakness in their hindlimbs. The mean age at which this clinical weakness appeared in the H46R-70 line was 153 T 10.0 days (n = 4). As the disease progressed, the mice exhibited marked muscle wasting in their limbs. Thereafter, the other limbs also became weak. At the end stage of disease, the affected mice were unable to move toward water to drink and they died. The mean ages at death in the H46R-70 line were 184 T 11.8 days (n = 4). The mean duration of the clinical expression of the disease in the H46R-70 was 27.5 T 8.2 days (n = 4). The lines that expressed lower levels of human mutant SOD1 did not show any clinical phenotypes at 12 months of age.
Histopathology
A total of 8 Tg mice and 8 age-matched nontransgenic (non-Tg) mice were investigated, respectively. Eight Tg mice were divided into 4 groups: early presymptomatic (aged 12 weeks, n = 2), late presymptomatic (16 weeks, n = 2), early symptomatic (20 weeks, n = 2), and end-stage Tg mice (24 weeks, n = 2). Age-matched non-Tg mice served as controls in each group (n = 8). Tg and non-Tg mice were examined simultaneously. All mice (n = 16) were deeply anesthetized with ether and perfused intracardially with heparinized saline (pH 7.4), followed by perfusion with ice-cold 4% paraformaldehyde (Katayama Chemical, Osaka, Japan) in 0.1 M phosphate buffer (pH 7.4). The spinal cord was removed rapidly and post-fixed by immersion in the same fixative (5 days, 4-C). Cross-sections of the spinal cord were embedded in paraffin, sectioned (4 Km), and subsequently stained with hematoxylin and eosin (H&E) and Klüver-Barrera stain.
Immunohistochemistry
The following antibodies were used in this study: a sheep polyclonal anti-human SOD1 antibody (Calbiochem; diluted 1:1,000), a polyclonal anti-ubiquitin antibody (diluted 1:10; Sigma), a polyclonal anti-glial fibrillary acidic protein (GFAP) antibody (diluted 1:750; DAKO, Glostrup, Denmark), a mouse monoclonal antibody to rat phosphorylated neurofilament (SMI-31, diluted 1:1000; Sternberger Monoclonals, Lutherville, MD), a polyclonal antibody against a synthetic peptide corresponding to amino acid residues 124 to 134 of human >-synuclein with phosphoserine 129 (PSer 129, diluted 1:1000; a gift from Dr. T. Iwatsubo [14] ), and a mouse monoclonal phosphorylated tau (AT8) (diluted 1:1000; Innogenetics, Ghent, Belgium). Sections (4-Km-thick) of the paraffin-embedded spinal cords were deparaffinized and treated with nonimmune serum as the blocking reagent, and the reaction was quenched with 3% H 2 O 2 . The samples were then incubated overnight at 4-C with the primary antibodies. Antibody binding was visualized by the avidin-biotin-immunoperoxidase complex (ABC) method using an Elite ABC kit (Vector Laboratories, Burlingame, CA) following the manufacturer's recommendations. 3,3`-diaminobenzidine tetrahydrochloride was the final chromogen. Selected sections were incubated with the antibodies against phosphorylated neurofilament, ubiquitin, and SOD1 that had been preabsorbed with excess amounts of these antibodies. Sections from which the primary antibodies had been omitted served as negative reaction controls.
Electron Microscopy
Eight Tg and 8 non-Tg wild-type mice were killed at ages 12, 16, 20, and 24 weeks (n = 2 in each group, respectively). All mice were perfused intracardially with heparinized saline (pH 7.4) followed by perfusion with icecold 4% paraformaldehyde (Katayama Chemical, Osaka, Japan) and 0.2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Tissues of the spinal cord were incubated in 2% osmium tetroxide in 0.1 M cacodylate for 2 hours, washed, dehydrated, and embedded in epoxy resin. Serial semithin sections (1 Km) of the whole transverse spinal cord stained with toluidine blue were examined under a light microscope. Appropriate portions were cut into ultrathin sections, which were subsequently stained with lead citrate and uranyl acetate for electron microscopic study.
Immunoelectron Microscopy
Postembedding immunogold electron microscopy was carried out on spinal cord specimens. Late presymptomatic (16 weeks, n = 1), early symptomatic (20 weeks, n = 1), and end-stage (24 weeks, n = 1) mice were perfused intracardially with heparinized saline (pH 7.4) followed by 100 mM phosphate buffer (pH 7.4) containing ice-cold 4% paraformaldehyde and 0.1% glutaraldehyde. Two non-Tg wild-type mice (20 weeks, n = 1; 24 weeks, n = 1) served as controls. The lumbar and cervical spinal cord from fixed mice were dissected out, dehydrated in 100% ethanol, and embedded in hard-grade LR White resin (Electron Microscopy Sciences, Fort Washington, PA) by polymerization overnight at 60-C. Ultrathin sections were excised from the embedded tissue using a microtome, and the sections were collected onto grids (150 mesh). Then, the ultrathin sections were etched in 0.1 N HCl for 5 minutes, rinsed 3 times for 5 minutes each in Tris-buffered saline (TBS) (20 mM Tris, 140 mM NaCl, and 2.7 mM KCl, pH 8.0), treated with blocking buffer (0.1% gelatin, 1% normal goat serum, and 0.3% Triton-X-100 in TBS) for 30 minutes, incubated with the primary antibodies for 2 hours at room temperature, rinsed 3 times for 5 minutes each in TBS, placed in goldconjugated secondary antibody (10 nm gold anti-mouse antirabbit) for 1 hour, rinsed 3 times in TBS, rinsed in water, stained with Reynold's lead citrate followed by staining with aqueous 2% uranyl acetate, and then dried on filter paper. The following antibodies and sera were used: a sheep polyclonal anti-human SOD1 antibody at 1:500, 1:1000, or 1:2000 (Calbiochem) dilution; a polyclonal anti-ubiquitin antibody (DAKO) diluted at 1:100, 1:500, or 1:1000; a monoclonal anti-phosphorylated neurofilament antibody (DAKO) diluted at 1:50, 1:100, 1:500, and normal rabbit serum (Vector Laboratories).
RESULTS

Light Microscopic Findings
In 12-week-old mice (early presymptomatic stage) the H&E and Klüver-Barrera staining revealed no pathologic changes such as vacuolar changes or neuronal loss anywhere in the spinal cord (Fig. 1A) . The average number of large anterior horn neurons, which measured more than 18 Km in diameter (i.e. the mean of the shortest and the largest diameters of an anterior horn cell) per anterior horn was 15.7 T 1.2 (n = 6 sections); thus, no significant differences from controls were observed in the experimental mice by either staining (H&E or Klüver-Barrera) or by neuronal count and measurement at this stage. Furthermore, no Lewy body-like inclusions (LIs) were observed anywhere in the samples by H&E staining. However, on Epon-embedded plastic sections stained with toluidine blue, rare aggregates and LIs were detected in the neuropil of the anterior horns and around the central canal, but not in the posterior horns or white matter. The anterior and posterior roots showed no abnormalities.
In 16-week-old mice (late presymptomatic stage), H&E and Klüver-Barrera staining revealed no pathologic changes in either the gray matter or the white matter. Aggregates and LIs were rarely observed by H&E staining. The average number of anterior horn neurons was 14.2 T 1.5 (n = 6 sections), showing no significant difference from the controls. On plastic sections, occasional aggregates and LIs were seen in the neuropil in the anterior horns, as were spheroids and cord-like swollen axons ( Fig. 2A) . LIs frequently contained cores at the center. Myelin ovoids were only occasionally observed in all white matter examined, but the anterior and posterior roots were intact.
In 20-week-old mice (early symptomatic stage), loss of anterior horn neurons with astrogliosis was observed, and the average number of large anterior horn neurons was 6.0 T 1.4 (n = 6 sections), which was significantly fewer than that of the controls (p G 0.01) (Fig. 1B) . Aggregates and LIs were occasionally observed in the anterior horn by H&E staining. On plastic sections, LIs (Fig. 2B) , spheroids, and cord-like swollen axons were frequently seen in the neuropil of anterior horns (Fig. 2C) . The white matter exhibited slight myelin ovoid formation in the anterior, lateral, and posterior columns (Fig. 2D) . The anterior roots showed slight myelin ovoids, whereas the posterior roots were free of myelin ovoids.
In 24-week-old mice (end stage), loss of anterior horn neurons accompanied by astrogliosis was remarkable. The average number of anterior horn neurons was 4.8 T 1.5 (n = 6 sections). Aggregates and LIs were frequently observed in the neuropil of the anterior horn by H&E staining (Fig. 2E) . On the plastic sections, LIs were frequently seen both in the neuropil and in the cord-like swollen axons of the anterior horns; moreover, LIs were also observed in the posterior horns and in the white matter of the anterior, lateral, and posterior columns. Swollen axons (spheroids) were prominent in the exit zone of the anterior roots in the anterior columns as well as in the anterior horns. Myelin ovoids and degenerated fibers were prominent in the anterior roots (Fig. 2F , G) and posterior roots (Fig. 2H, I ), as well as in the white matter of the anterior, lateral, and posterior columns, including the pyramidal tract (Fig. 2J, K) . No vacuolar changes were observed anywhere at any stage.
Immunohistochemical Findings
In mice at the early presymptomatic stage of disease, SOD1-and ubiquitin-positive granular and linear deposits were only occasionally found in the neuropils of the anterior horns. No immunohistochemical abnormalities were revealed by antiphosphorylated neurofilament or GFAP antibodies, either in the gray or the white matter.
In mice at the late presymptomatic stage, many more SOD1-and ubiquitin-positive aggregates and LIs were observed in the neuropils of the anterior horns than at the previous stage of disease. Phosphorylated neurofilamentpositive spheroids were only occasionally observed in the anterior and lateral columns adjacent to the surface (leptomeninx) of the spinal cord but not in the anterior and posterior roots. The number of GFAP-positive astrocytes increased in the anterior horn, but no such increase was observed in the white matter.
At the early symptomatic stage, SOD1-and ubiquitinpositive aggregates and LIs were observed in the anterior and, to a lesser extent, in the posterior horns and in the white matter of the anterior, lateral, and posterior columns. Phosphorylated neurofilament-positive spheroids were frequently observed in the posterior column as well as in the anterior and lateral columns and anterior roots; to a lesser extent, phosphorylated neurofilament-positive spheroids were observed in the posterior roots. The number of GFAP-positive astrocytes increased in the anterior horn, but no such increase was observed in the white matter.
In end-stage mice, SOD1-and ubiquitin-positive deposits were more predominantly observed in the white matter (as well as in the gray matter of the anterior and posterior horns) than at the early symptomatic stage (Fig. 3) . Many spheroids or swollen axons showed positive immunostaining of phosphorylated neurofilaments in the anterior horns (Fig. 4) and in the anterior and posterior roots. The number of GFAP-positive astrocytes increased in the anterior horn and, to a lesser extent, in the anterior and lateral columns.
Aggregates and LIs were not immunostained for phosphorylated neurofilament (SMI-31). The spinal cord did not show any phosphorylated >-synuclein (PSer 129) or phosphorylated tau (AT8) immunoreactivity.
Electron Microscopic Findings
In mice at the early presymptomatic stage of disease (12 weeks), no definite abnormalities were detected, with the exception of tiny filamentous aggregates lacking electrondense cores, which were only occasionally present in the neuronal processes in the anterior horns. In mice at the late presymptomatic stage (16 weeks), filamentous aggregates were not uncommonly observed in the neuronal processes, including the axons in the anterior horns. No aggregates were found in the somata or proximal dendrites of the anterior horn cells. In mice at the symptomatic stage (20 and 24 weeks), filamentous aggregates were frequently present and were predominantly found in the neuronal processes, including the proximal axons in the anterior horns. Moreover, aggregates were occasionally observed in the cytoplasm of astrocytes. The aggregates almost always consisted of interwoven intermediate filaments (~10Y15 nm in diameter) that were slightly thicker than neurofilaments (Fig. 5) . These aggregates were composed of loosely or compactly packed filaments and frequently contained electron-dense granular or amorphous cores at the center; as such, these aggregates with cores resembled LIs. On the other hand, the aggregates were less frequently observed in the somata or dendrites of the anterior horn neurons. Usually a single but occasionally a few aggregates were observed in the soma of a single neuron. Cord-like swollen axons with or without a myelin sheath consisted of accumulated neurofilaments running parallel to the longitudinal axis, which frequently contained filamentous aggregates and LIs. Vacuolated mitochondria were not found anywhere at any stage.
Immunoelectron Microscopic Findings
To determine the ultrastructural distribution of human SOD1 and ubiquitin immunoreactivity, we used postembedding immunogold electron microscopy. A sheep polyclonal anti-human SOD1 antibody (Calbiochem) at a dilution of 1:1000 and a polyclonal anti-ubiquitin antibody (DAKO) at a dilution of 1:500 were ideal for the detection of deposits of immunogold particles in the aggregates. Aggregates were easily identified by their characteristic structure. High levels of human SOD1 (Fig. 6 ) and ubiquitin-immunogold labeling (Fig. 7) were observed in the profiles of small to large aggregates, even in samples obtained at the presymptomatic stage. Compactly packed filaments and electron-dense cores of aggregates showed more prominent SOD1-and ubiquitinimmunogold labeling than did loosely packed filaments. There were no significant immunogold-labeled deposits of SOD1 or ubiquitin in the mitochondria. Phosphorylated neurofilament-immunogold labeling was not detected in the aggregates.
Nontransgenic Littermates
The average number of anterior horn neurons was 14.5 T 1.9 (n = 6). No vacuolar changes were observed. No control mice at any age showed SOD1-or ubiquitin-positive aggregates, LIs, or cord-like axonal swelling. 
DISCUSSION
Two main pathologic features of human mutant SOD1 Tg mice include vacuolar formation (15Y18) and the presence of SOD1-and ubiquitin-positive aggregates (19Y22). Vacuolar formation has been identified as a dominant pathologic feature associated with motor neuron death and paralysis in mice expressing G93A or G37R mutant SOD1 (15Y18), although there remains some controversy regarding the origin and the site of vacuoles. Vacuolar pathology that at least partially represents damaged mitochondria is seen in the motor neurons of mice or rats expressing high levels of SOD1 G93A (23Y25) and SOD1 G37R (26), but it is not seen in diseases associated with other mutations (8, 27) . Mice expressing high gene copy numbers of human SOD1 carrying the G93A mutation developed a disease with a relatively short course and with a pathology primarily characterized by severe vacuolar changes in the anterior horn neurons and their processes (23) . On the other hand, G93A mutant SOD1 Tg mice with a low transgene copy number showed no vacuoles (28) . Vacuolar changes are also less apparent in affected H46R rats (8) . The present study of H46R mutant SOD1 Tg mice has revealed an initial development of muscle weakness and atrophy in the hindlimbs, as well as an absence of vacuolar formation anywhere at any stage of the disease; these features are compatible with the clinical and pathologic manifestations of patients with FALS who have an H46R mutant SOD1 gene (4Y6). Our findings suggest that vacuolar formation may not play a critical role in the pathogenesis in H46R mutant SOD1 Tg mice or patients with an H46R mutant SOD1 gene.
On the other hand, a feature common to all examples of SOD1 mutant-mediated disease in mice is prominent SOD1-and ubiquitin-positive aggregates. SOD1-positive aggregates have been implicated as a potential mechanism in the pathogenesis of mutant SOD1 Tg mice (19Y22), although discrepancies have been reported in terms of both the location and distribution of aggregates. H46R rats have an abundance of aggregates, particularly late in the course of disease (8) . This is the first report to demonstrate the fine structure of aggregates in H46R mutant SOD1 Tg mice, in which SOD1-and ubiquitin-positive aggregates were observed as diffusely and prominently present at quite an early phase of the presymptomatic stage, primarily in the anterior horns and, to a lesser extent, in the posterior horns and the white matter, including the anterior and posterior columns; in addition, this study showed marked increases in the size and frequency of these aggregates with disease progression. Another novel finding of the present study was the electron microscopic detection of tiny aggregates in the neuropil of the anterior horn, even at the early presymptomatic stage of disease. The present results, taken together with those of preceding reports, suggest that such aggregates are characteristic of SOD1 mutant mice and rats, although the particular site and distribution of aggregates differ somewhat among reports. Thus, it is likely that such aggregates are involved in the pathomechanism of motor neuron degeneration, although it remains unclear whether or not they play a neurotoxic or neuroprotective role.
Previous reports of other mutant SOD1 Tg mice have noted pathologic changes that are relatively restricted to the anterior horns of the spinal cord (15, 26, 28, 29) : in the spinal cord of G86R SOD1 Tg mice, there is no significant reduction in the number of total neurons, motor neurons, or interneurons in the ventral spinal cord of presymptomatic mice (29) ; in the intermediate and late stages of degeneration in the spinal cord of G37R SOD1 Tg mice, there is no degeneration of the ventral, lateral, or dorsal columns, and even at more advanced stages there is no evidence of axonal degeneration in the corticospinal tract of the dorsal column (26) . In the spinal cord of G93A SOD1 Tg mice that highly express the mutated gene (the G1 line), the main changes observed are primarily limited to the neuronal cell body; the white matter of the anterior, lateral, and posterior columns remains essentially normal at the presymptomatic and early symptomatic stages, whereas at the symptomatic stage, changes in the white matter (axonal degeneration) are localized in the anterior and lateral columns (15) . On the other hand, in the spinal cord of G93A SOD1 Tg mice, a line of low expressors of the mutated gene (G5/G5), the white matter of the anterior, lateral, and the intermediate zone of the posterior columns shows abnormalities after 200 days of age (i.e. clinical signs develop after 300 days of age), whereas the posterior roots are essentially normal, even at the symptomatic stage (28) . It was thus a novel finding of the present study that in the spinal cord of H46R Tg mice, axonal degeneration extended beyond the motor system to the entire white matter, including the pyramidal tract of the posterior column and the anterior and posterior roots, as detected on Eponembedded plastic sections by toluidine blue staining. These neuropathologic changes are mostly consistent with those of H46R rats (8) ; namely, in H46R rats at the presymptomatic stage, an increased number of reactive astrocytes and a reduction in the number of large anterior horn neurons are observed, together with an increase in the number of microglia in the anterior horn; ubiquitination of the dendrites and axons are evident in the anterior horn of the lumbar spinal cord, and at the symptomatic stage there is a marked loss of large motor neurons as well as site of swelling in the axons in the anterior horn (8) . However, there is no description of the involvement of the white matter, anterior roots, or posterior roots in H46R rats. Aggregates and LIs are observed after the onset of clinical signs in H46R rats, whereas H46R mice already show such signs, primarily in the anterior horns, even at the presymptomatic stage. In this study, the ultrastructures of the aggregates and LIs, both of which consisted of interwoven intermediate filaments, showed deposits of ubiquitin-and SOD1-immunogold labeling; these results are consistent with those described in previous reports on other mutant SOD1 Tg mice such as G93A mice (22) .
In autopsy cases of patients FALS who had an H46R mutation in the SOD1 gene, SOD1-and ubiquitin-positive aggregates and inclusions are not present in the spinal cord, including the neuropil and the remaining anterior horn cells (5, 6) . This feature stands in contrast to the presence of LIs in H46R mutant SOD1 Tg mice; the difference is probably due to a longstanding course in affected humans with a severe depletion of anterior horn neurons. Moreover, in 1 of 2 autopsy reports, the corticospinal tracts, posterior column, and anterior and posterior spinocerebellar tracts were found to be degenerated (5) , whereas in the other report, the lateral columns, including the spinocerebellar tracts and the anterior funiculi, were atrophic, although the posterior column was preserved (6) . These previous findings are consistent with the present findings obtained with H46R mutant SOD1 Tg mice in that the degenerative changes extend over the entire white matter (including the anterior, lateral, and posterior columns) with time.
Thus, the H46R SOD1 mutation is clinically characterized as a Bpseudopolyneuritic form of ALS^with lower motor neuron-dominant involvement developing in the lower extremities and a markedly longstanding clinical course, and pathologic, widespread changes extending beyond the motor system to the entire white matter, and the anterior and posterior roots; in this line of mutant mice, these features are accompanied by numerous SOD1-and ubiquitin-positive aggregates lacking vacuoles. This animal model of H46R mutant SOD1 Tg mice is suitable for the investigation of human FALS with an H46R mutant SOD1 gene because of the close pathologic similarity between the 2 diseases. Further examination is needed to locate the site at which the aggregates predominate and originate (e.g. in the somata of the anterior horn neurons, dendrites, axons, or non-neuronal cells [astrocytes and microglia]). It will also be necessary to elucidate whether these aggregates are neurotoxic and thereby involved in the pathomechanism in these Tg mice or whether they are only a bystander and instead exert some neuroprotective function.
